Effective Immunotherapy Treatment for Penile Cancer

Rare penile cancer known as penile squamous cell carcinoma has few curative possibilities. Immune checkpoint inhibitors (ICIs) may provide certain patients with advanced penile squamous cell carcinoma with promising therapeutic advantages, according to a global study conducted by Yale Cancer Center researchers at Yale School of Medicine. Immunotherapy medications known as immune checkpoint inhibitors prevent checkpoint proteins from interacting with their companion proteins.

The report was released on August 11 in the National Cancer Institute Journal.

“These findings provide encouraging evidence that immune checkpoint inhibitors can be effective in treating a subset of patients with penile squamous cell carcinoma,” said co-first author Amin Nassar, a member of Yale Cancer Center and a clinical fellow at Yale School of Medicine. We believe that further translational studies and biomarker-based research are essential to identify patients most likely to benefit from this therapy and improve the outcomes for individuals with penile cancer.

The effectiveness of ICIs was evaluated in this study between 2015 and 2022 by concentrating on a global cohort of 92 patients with locally progressed or metastatic penile cancer. Pembrolizumab, Nivolumab, and Cemiplimab were the most often given ICIs, while some patients also received Nivolumab and Ipilimumab in combination therapy.

35% of patients with lymph node-only metastases and 13% of all patients reacted to ICIs, according to research. Patients had an average overall survival rate of 9.8 months. 29% of patients experienced negative side effects from their treatments.